This work is licensed under a
Creative Commons Attribution 4.0 International License
L.A. Donehower, M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery, J.S. Butel, A. Bradley, L.A. Donehower, M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery, J.S. Butel, A. Bradley, Mice deficient for p.53 are developmentally normal but susceptible to spontaneous tumours, Nature, 356 (1992).
D. Bernard, Y. Zhao, S. Wang, AM-8553: a novel MDM2 inhibitor with a promising outlook for potential clinical development, J. Med. Chem. 55 (2012) 4934-4935.
S.A.A. Anand, C. Loganathan, N.S. Thomas, K. Saravanan, A.T. Alphonsa, S. Kabilan, Synthesis, structure prediction, pharmacokinetic properties, molecular docking and antitumor activities of some novel thiazinone derivatives, New J. Chem. 39 (2015).
H. Yamashita, K. Ohno, H. Inami, J. Shishikura, S. Sakamoto, M. Okada, T. Yamaguchi, Suppression of fully kindled seizure and retardation of kindling acquisition by YM928 in the rat kindling model of epilepsy, Eur. J. Pharmacol. 494 (2004).
L.D.S. Yadav, A.R. Misra, H. Singh, Ring transformation of Michael adducts of Benzylidene-5-oxazolones and 3-mercapto-s-triazoles to 2, 3-dihydro-4H-s-triazolo[3, 4b][1, 3] thiazin-4-ones with some antifungal activity, J. Agric. Food Chem. 36 (1988).
V.V. Kouznetsov, A.G. Barrio, Recent developments in the design and synthesis of hybrid molecules based on aminoquinoline ring and their antiplasmodial evaluation, Eur. J. Med. Chem. 44 (2009) 3091-3113.
J. Matysiak, M. Juszczak, M.M. Karpińska, E. Langner, K. Walczak, M.K. Lemieszek, A. Skrzypek, A. Niewiadomy, W. Rzeski, Synthesis of 2-(2, 4-dihydroxyphenyl)thieno-1, 3-thiazin4-ones, their lipophilicity and anticancer activity in vitro, Mol. divers. (2015).
K. Ohno, R. Tsutsumi, N. Matsumoto, H. Yamashita, Y. Amada, J. Shishikura, H.I.S. Yatsugi, M. Okada, S. Sakamoto and T. Yamaguchi, Functional characterization of YM928, a novel moncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, J. Pharmacol. Exp. Ther. 306 (2003).
K. Michelsen, J.B. Jordan, J. Lewis , A.M. Long, E. Yang , Y. Rew, J. Zhou , P. Yakowec, P.D. Schnier , X. Huang , L. Poppe, Ordering of the N-terminus of human MDM2 by small molecule inhibitors, J. Am. Chem. Soc. 134 (2012) 17059-17067.
Protein Preparation Wizard; Epik version 2. 3, 2014; Impact version 5. 7, 2014, Schrödinger, LLC, New York.
Maestro, 2014 release, Schrödinger suite, LLC, New York, (2014).
W.L. Jorgensen, D.S. Maxwell, J. Tirado-Rives, Development and testing of the OPLS allatom force field on conformational energetics and properties of organic liquids, J. Am. Chem. Soc. 118 (1996) 11225-11236.
LigPrep, version 2. 5, 2014, Schrödinger, LLC, New York.
Glide, version 5. 8, 2014, Schrödinger, LLC, New York.
Desmond Molecular Dynamics System, version 3. 1, 2012, D. E. Shaw Research, New York, Maestro-Desmond Interoperability Tools, version 3. 1, 2012, Schrödinger, New York.
W.L. Jorgensen, J. Chandrasekhar, J.D. Madura, R.W. Impey, M.L. Klein, Comparison of simple potential functions for simulating liquid water, J. Chem. Phys. 79 (1983) 926-935.
W.G. Hoover, Canonical dynamics: Equilibrium phase-space distributions, Phys. Rev. A. 31 (1985) 1695-1697.
G.J. Martyna, D.J. Tobias, M.L. Klein, Constant pressure molecular dynamics algorithms, J. Chem. Phys. 101 (1994) 4177-4189.
U. Essmann, L. Perera, M.L. Berkowitz, T. Darden, H. Lee, L.G. Pedersen, A smooth particle mesh Ewald method, J. Chem. Phys. 103 (1995) 8577-8859.
F. Gonzalez-Lopez de Turiso, D. Sun, Y. Rew, M.D. Bartberger, H.P. Beck, J. Canon, A. Chen, D. Chow, T.L. Correll, X. Huang, L.D. Julian, F. Kayser, M.C. Lo, A.M. Long, D. McMinn, J.D. Oliner, T. Osgood, J.P. Powers, A.Y. Saiki, S. Schneider, P. Shaffer, S.H. Xiao, P. Yakowek, X. Yan, Q. Ye, D. Yu, X. Zhao, J. Zhou, J.C. Medina, S.H. Olson, Rational design and binding mode duality of MDM2-p.53 inhibitors, J. Med. Chem. 56 (2013).
[1] H. Arjun, R. Elancheran, N. Manikandan, K. Lakshmithendral, M. Ramanathan, A. Bhattacharjee, N. Lokanath, S. Kabilan, "Design, Synthesis, and Biological Evaluation of (E)-N'-((1-Chloro-3,4-Dihydronaphthalen-2-yl)Methylene)Benzohydrazide Derivatives as Anti-prostate Cancer Agents", Frontiers in Chemistry, Vol. 7, 2019
DOI: https://doi.org/10.3389/fchem.2019.00474[2] A. Ananth, N. Manikandan, R. Rajan, R. Elancheran, K. Lakshmithendral, M. Ramanathan, A. Bhattacharjee, S. Kabilan, "Design, Synthesis, and Biological Evaluation of 2‐(2‐Bromo‐3‐nitrophenyl)‐5‐phenyl‐1,3,4‐oxadiazole Derivatives as Possible Anti‐Breast Cancer Agents", Chemistry & Biodiversity, 2020
DOI: https://doi.org/10.1002/cbdv.201900659[3] H. Arjun, R. Rajan, R. Elancheran, M. Ramanathan, A. Bhattacharjee, S. Kabilan, "Crystal structure, Hirshfeld surface analysis, DFT and molecular docking studies on benzohydrazide derivatives as potential inhibitors of prostate cancer", Chemical Data Collections, p. 100350, 2020
DOI: https://doi.org/10.1016/j.cdc.2020.100350